Project Details
Description
Phase II Study of the Trifunctional Bispecific Anti-HER-2/Neu x Anti-CD3 Antibody Ertumaxomab in Patients with HER-2/Neu Overexpressing (3+ or 2+/FISH+) Metastatic Breast
Status | Finished |
---|---|
Effective start/end date | 6/1/07 → 12/31/10 |
Funding
- FRESENIUS BIOTECH NORTH AMERICA INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.